Systematic sextant biopsies improve preoperative prediction of pelvic lymph node metastases in patients with clinically localized prostatic carcinoma

被引:62
作者
Conrad, S [1 ]
Graefen, M
Pichlmeier, U
Henke, RP
Hammerer, PG
Huland, H
机构
[1] Inst Math & Comp Sci Med, Dept Urol, Hamburg, Germany
[2] Univ Hamburg, Eppendorf Univ Hosp, Inst Pathol, Hamburg, Germany
关键词
prostatic neoplasms; lymph node excision; neoplasm metastasis; biopsy;
D O I
10.1016/S0022-5347(01)63234-8
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: An algorithm including the results of systematic sextant biopsies was statistically developed and evaluated to predict the probability of pelvic lymph node metastases in patients with clinically localized carcinoma of the prostate. Materials and Methods: Clinical stage, serum prostate specific antigen concentration, Gleason score, number of positive biopsies, number of biopsies containing any Gleason grade 4 or 5 cancer and number of biopsies predominated by Gleason grade 4 or 5 cancer were recorded in 345 patients undergoing pelvic lymph node dissection and correlated with the incidence of lymph node metastases. Multivariate logistic regression, and classification and regression trees analyses were performed. Results: In univariate analysis all variables had a statistically significant influence on lymph node status. Logistic regression showed that the amount and distribution of undifferentiated Gleason grade 4 and 5 cancer in the biopsies were the best predictors of lymphatic spread followed by serum prostate specific antigen. Classification and regression trees analysis classified 79.9% of patients who had 3 or fewer biopsies with Gleason grade 4 or 5 cancer and no biopsies predominated by undifferentiated cancer as a low risk group. In this group positive lymph nodes occurred in only 2.2% (95% confidence interval 0.8 to 4.7%). Conclusions: Including the results of systematic sextant biopsies substantially enhances the predictive accuracy of algorithms that define the probability of lymph node metastases in prostatic cancer. Patients thus defined as having no lymphatic spread could potentially be spared pelvic lymph node dissection before definitive local treatment.
引用
收藏
页码:2023 / 2029
页数:7
相关论文
共 51 条
  • [1] ANALYSIS OF RISK-FACTORS ASSOCIATED WITH PROSTATE-CANCER EXTENSION TO THE SURGICAL MARGIN AND PELVIC NODE METASTASIS AT RADICAL PROSTATECTOMY
    ACKERMAN, DA
    BARRY, JM
    WICKLUND, RA
    OLSON, N
    LOWE, BA
    [J]. JOURNAL OF UROLOGY, 1993, 150 (06) : 1845 - 1850
  • [2] [Anonymous], UROLOGIC PATHOLOGY
  • [3] DNA-PLOIDY, SERUM PROSTATE-SPECIFIC ANTIGEN, HISTOLOGICAL GRADE AND IMMUNOHISTOCHEMISTRY AS PREDICTIVE PARAMETERS OF LYMPH-NODE METASTASES IN T1-T3/MO PROSTATIC ADENOCARCINOMA
    BERNER, A
    WAERE, H
    NESLAND, JM
    PAUS, E
    DANIELSEN, HE
    FOSSA, SD
    [J]. BRITISH JOURNAL OF UROLOGY, 1995, 75 (01): : 26 - 32
  • [4] PELVIC LYMPHADENECTOMY CAN BE OMITTED IN SELECTED PATIENTS WITH CARCINOMA OF THE PROSTATE - DEVELOPMENT OF A SYSTEM OF PATIENT SELECTION
    BISHOFF, JT
    REYES, A
    THOMPSON, IM
    HARRIS, MJ
    STCLAIR, SR
    GOMELLA, L
    BUTZIN, CA
    [J]. UROLOGY, 1995, 45 (02) : 270 - 274
  • [5] ELIMINATING THE NEED FOR BILATERAL PELVIC LYMPHADENECTOMY IN SELECT PATIENTS WITH PROSTATE-CANCER
    BLUESTEIN, DL
    BOSTWICK, DG
    BERGSTRALH, EJ
    OESTERLING, JE
    [J]. JOURNAL OF UROLOGY, 1994, 151 (05) : 1315 - 1320
  • [6] OPEN PELVIC LYMPH-NODE DISSECTION FOR PROSTATE-CANCER - A REASSESSMENT
    CAMPBELL, SC
    KLEIN, EA
    LEVIN, HS
    PIEDMONTE, MR
    [J]. UROLOGY, 1995, 46 (03) : 352 - 355
  • [7] CHENG CWS, 1993, CANCER, V71, P996, DOI 10.1002/1097-0142(19930201)71:3+<996::AID-CNCR2820711417>3.0.CO
  • [8] 2-8
  • [9] THE CONTEMPORARY INCIDENCE OF LYMPH-NODE METASTASES IN PROSTATE-CANCER - IMPLICATIONS FOR LAPAROSCOPIC LYMPH-NODE DISSECTION
    DANELLA, JF
    DEKERNION, JB
    SMITH, RB
    STECKEL, J
    [J]. JOURNAL OF UROLOGY, 1993, 149 (06) : 1488 - 1491
  • [10] DAVIS GL, 1995, CANCER, V76, P661, DOI 10.1002/1097-0142(19950815)76:4<661::AID-CNCR2820760419>3.0.CO